Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The last few months have seen a flurry of trial results for investigational agents in Alzheimer's disease (AD). This analysis investigates the different categories of developmental drugs in AD, and provides an outlook to the future of the AD market.
An analysis of recent approved and failed marketing applications for new drugs evaluated by the European Medicines Agency highlights the factors that are most likely to be associated with non-approval.
The market for drugs to treat wet age-related macular degeneration (AMD) is expected to more than double by 2016. This article investigates unmet needs and discusses current agents in the pipeline.
The developmental pipeline for drugs to treat autism spectrum disorders (ASDs) has more than doubled since April last year, and each candidate in clinical development targets a different mechanism of action. This article investigates the ASD market and provides an overview of experimental therapies.
In the wake of the recent approvals of the first new obesity therapies in more than a decade, Wong and colleagues analyse their market prospects as well as the late-stage pipeline.
This article investigates current unmet needs in the treatment of sleep disorders, and how understanding of their molecular biology has led to the development of exciting pipeline candidates.
This analysis of the outcomes of advisory committee meetings held by the US Food and Drug Administration (FDA) over the past decade investigates issues such as the consistency between advisory committee votes and FDA approval decisions.
Analysis of industry pipeline data and revenue forecasts highlights several trends in the anticipated output of new drugs and the therapeutic area focus over the next 5 years, including a growth in the average number of new drug approvals annually.
This article analyses the relationship between risk and the cost of capital for projects in different stages of drug development and describes a framework that could improve portfolio optimization strategies.
Rare diseases affect, by definition, only a small number of people. This article investigates how drug development for rare diseases can provide attractive opportunities for biopharmaceutical industries.
This article examines strategic issues faced by pharmaceutical companies relating to the development of biomarkers and diagnostics for Alzheimer's disease.
Data on indicators such as the number and success rate of research and development projects illustrate trends in the pharmaceutical industry over the past decade.
